Skip to main content
SpringerLink
Log in

Monoclonal Antibodies

  • Protocol
Molecular Biomethods Handbook

Part of the book series: Springer Protocols Handbooks ((SPH))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting anti-body of predefined specificity. Nature 256:495–497

    Article  PubMed  CAS  Google Scholar 

  2. Franklin EC (1975) Structure and function of immunoglobulins. Acta Endocrinol Suppl (Copenh) 194:77–95

    CAS  Google Scholar 

  3. Leenaars M, Hendriksen CF (2005) Critical steps in the production of polyclonal and monoclonal antibodies: evaluation and recommendations. ILAR J 46:269–279

    PubMed  CAS  Google Scholar 

  4. Schroff RW, Foon KA, Beatty SM, Oldham RK, Morgan AC, Jr (1985) Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res 45:879–885

    PubMed  CAS  Google Scholar 

  5. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT (1984) Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 81:6851–6855

    Article  PubMed  CAS  Google Scholar 

  6. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G (1986) Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321:522–525

    Article  PubMed  CAS  Google Scholar 

  7. Roque-Navarro L, Mateo C, Lombardero J, Mustelier G, Fernandez A, Sosa K, Morrison SL, Perez R (2003) Humanization of predicted T-cell epitopes reduces the immunogenicity of chimeric antibodies: new evidence supporting a simple method. Hybrid Hybridomics 22:245–257

    Article  PubMed  CAS  Google Scholar 

  8. Mateo C, Lombardero J, Moreno E, Morales A, Bombino G, Coloma J, Wims L, Morrison SL, Perez R (2000) Removal of amphipathic epitopes from genetically engineered antibodies: production of modified immunoglobulins with reduced immunogenicity. Hybridoma 19:463–471

    Article  PubMed  CAS  Google Scholar 

  9. Huls GA, Heijnen IA, Cuomo ME, Koningsberger JC, Wiegman L, Boel E, van der Vuurst de Vries AR, Loyson SA, Helfrich W, van Berge Henegouwen GR, van Meijer M, de Kruif J, Logtenberg T (1999) A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments. Nat Biotechnol 17:276–281

    Article  PubMed  CAS  Google Scholar 

  10. Karpas A, Dremucheva A, Czepulkowski BH (2001) A human myeloma cell line suitable for the generation of human monoclonal antibodies. Proc Natl Acad Sci USA 98:1799–1804

    Article  PubMed  CAS  Google Scholar 

  11. Davis CG, Jia XC, Feng X, Haak-Frendscho M (2004) Production of human antibodies from transgenic mice. Methods Mol Biol 248:191–200

    PubMed  CAS  Google Scholar 

  12. Ishida I, Tomizuka K, Yoshida H, Tahara T, Takahashi N, Ohguma A, Tanaka S, Umehashi M, Maeda H, Nozaki C, Halk E, Lonberg N (2002) Production of human monoclonal and polyclonal antibodies in TransChromo animals. Cloning Stem Cells 4:91–102

    Article  PubMed  CAS  Google Scholar 

  13. McCafferty J, Griffiths AD, Winter G, Chiswell DJ (1990) Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348:552–554

    Article  PubMed  CAS  Google Scholar 

  14. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee SM, Lee T, Pope SH, Riordan GS, Whitlow M (1988) Single-chain antigenbinding proteins. Science 242:423–426

    Article  PubMed  CAS  Google Scholar 

  15. Holliger P, Prospero T, Winter G (1993) “Diabodies”: small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 90:6444–6448

    Article  PubMed  CAS  Google Scholar 

  16. Iliades P, Kortt AA, Hudson PJ (1997) Triabodies: single chain Fv fragments without a linker form trivalent trimers. FEBS Lett 409:437–441

    Article  PubMed  CAS  Google Scholar 

  17. Hu S, Shively L, Raubitschek A, Sherman M, Williams LE, Wong JY, Shively JE, Wu AM (1996) Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 56:3055–3061

    PubMed  CAS  Google Scholar 

  18. Arndt MA, Krauss J, Kipriyanov SM, Pfreundschuh M, Little M (1999) A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin's tumors. Blood 94:2562–2568

    PubMed  CAS  Google Scholar 

  19. Polito L, Bolognesi A, Tazzari PL, Farini V, Lubelli C, Zinzani PL, Ricci F, Stirpe F (2004) The conjugate Rituximab/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with Fludarabine. Leukemia 18:1215–1222

    Article  PubMed  CAS  Google Scholar 

  20. Matthey B, Borchmann P, Schnell R, Tawadros S, Lange H, Huhn M, Klimka A, Tur MK, Barth S, Engert A, Hansen HP (2004) Metalloproteinase inhibition augments antitumor efficacy of the anti-CD30 immunotoxin Ki-3(scFv)-ETA' against human lymphomas in vivo. Int J Cancer 111:568–574

    Article  PubMed  CAS  Google Scholar 

  21. Yarden Y (2001) The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer 37 Suppl 4:S3–8

    Article  Google Scholar 

  22. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127–137

    Article  PubMed  CAS  Google Scholar 

  23. Salomon DS, Brandt R, Ciardiello F, Normanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183–232

    Article  PubMed  CAS  Google Scholar 

  24. Nicholson RI, Gee JM, Harper ME (2001) EGFR and cancer prognosis. Eur J Cancer 37 Suppl 4:S9–15

    Article  Google Scholar 

  25. Mendelsohn J, Baselga J (2003) Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21:2787–2799

    Article  PubMed  CAS  Google Scholar 

  26. Ennis BW, Lippman ME, Dickson RB (1991) The EGF receptor system as a target for antitumor therapy. Cancer Invest 9:553–562

    Article  PubMed  CAS  Google Scholar 

  27. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345

    Article  PubMed  CAS  Google Scholar 

  28. Frieze DA, McCune JS (2006) Current status of cetuximab for the treatment of patients with solid tumors. Ann Pharmacother 40:241–250

    Article  PubMed  CAS  Google Scholar 

  29. Astsaturov I, Cohen RB, Harari P (2006) Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer. Expert Rev Anticancer Ther 6:1179–1193

    Article  PubMed  CAS  Google Scholar 

  30. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182

    Article  PubMed  CAS  Google Scholar 

  31. Cell Markers and Cytogenetics Committees College of American Pathologists. (2002) Clinical laboratory assays for HER-2/neu amplification and overexpres-sion: quality assurance, standardization, and proficiency testing. Arch Pathol Lab Med 126:803–808

    Google Scholar 

  32. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM (1992) Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA. 89:4285–4289

    Article  PubMed  CAS  Google Scholar 

  33. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, Kerbel RS (1997) Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151:1523–1530

    PubMed  CAS  Google Scholar 

  34. Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6:443–446

    Article  PubMed  CAS  Google Scholar 

  35. Ocana A, Rodriguez CA, Cruz JJ (2005) Integrating trastuzumab in the treatment of breast cancer. Current status and future trends. Clin Transl Oncol 7:99, 100

    Article  PubMed  Google Scholar 

  36. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186

    Article  PubMed  CAS  Google Scholar 

  37. Ellis LM (2005) Bevacizumab. Nat Rev Drug Discov Suppl: S8, 9

    Google Scholar 

  38. Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391–400

    Article  PubMed  CAS  Google Scholar 

  39. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60–65

    Article  PubMed  CAS  Google Scholar 

  40. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363–372

    Article  PubMed  Google Scholar 

  41. Brekke OH, Sandlie I (2003) Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov 2:52–62

    Article  PubMed  CAS  Google Scholar 

  42. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825–2833

    PubMed  CAS  Google Scholar 

  43. Smith MR (2003) Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 22:7359–7368

    Article  PubMed  CAS  Google Scholar 

  44. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242

    Article  PubMed  CAS  Google Scholar 

  45. Buske C, Hiddemann W (2006) Rituximab maintenance therapy in indolent NHL: a clinical review. Leuk Res 30 Suppl 1:S11–15

    Article  Google Scholar 

  46. Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, Jonas C, Klippenstein D, Dallaire B, Varns C (1999) Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268–276

    PubMed  CAS  Google Scholar 

  47. Hainsworth JD, Litchy S, Barton JH, Houston GA, Hermann RC, Bradof JE, Greco FA, Minnie Pearl Cancer Research Network (2003) Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 21:1746–1751

    Article  PubMed  CAS  Google Scholar 

  48. Friedberg JW, Neuberg D, Gribben JG, Fisher DC, Canning C, Koval M, Poor CM, Green LM, Daley J, Soiffer R, Ritz J, Freedman AS (2002) Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br J Haematol 117:828–834

    Article  PubMed  CAS  Google Scholar 

  49. Dorner T (2006) Crossroads of B cell activation in autoimmunity: rationale of targeting B cells. J Rheumatol Suppl 77:3–11

    PubMed  Google Scholar 

  50. Looney RJ (2006) B cell-targeted therapy for rheumatoid arthritis: an update on the evidence. Drugs 66:625–639

    Article  PubMed  CAS  Google Scholar 

  51. Weide R, Heymanns J, Pandorf A, Koppler H (2003) Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy. Lupus 12:779–782

    Article  PubMed  CAS  Google Scholar 

  52. Hansen PB, Lauritzen AM (2005) Aplastic anemia successfully treated with rituxi-mab. Am J Hematol 80:292–294

    Article  PubMed  Google Scholar 

  53. Noss EH, Hausner-Sypek DL, Weinblatt ME (2006) Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 33:1021–1026

    PubMed  Google Scholar 

  54. Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, Andersen I, Schmidt K, Andersen TM, Peterslund NA, Birgens HS, Plesner T, Pedersen BB, Hasselbalch HC (2005) Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol 78:275–280

    Article  PubMed  CAS  Google Scholar 

  55. Salisbury JR, Rapson NF, Codd JD, Rogers MV, Nethersell AB (1994) Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas. J Clin Pathol 47:313–317

    Article  PubMed  CAS  Google Scholar 

  56. Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, Albitar M, Brettman L, Santabarbara P, Wacker B, Rai KR (2002) Therapeutic role of alemtuzumab (Campath-1 H) in patients who have failed fludarabine: results of a large international study. Blood 99:3554–3561

    Article  PubMed  CAS  Google Scholar 

  57. Faderl S, Coutre S, Byrd JC, Dearden C, Denes A, Dyer MJ, Gregory SA, Gribben JG, Hillmen P, Keating M, Rosen S, Venugopal P, Rai K (2005) The evolving role of alemtuzumab in management of patients with CLL. Leukemia 19:2147–2152

    Article  PubMed  CAS  Google Scholar 

  58. Osterborg A, Mellstedt H, Keating M (2002) Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia. Med Oncol 19 Suppl: S21–6

    Article  PubMed  Google Scholar 

  59. Faderl S, Thomas DA, O'Brien S, Garcia-Manero G, Kantarjian HM, Giles FJ, Koller C, Ferrajoli A, Verstovsek S, Pro B, Andreeff M, Beran M, Cortes J, Wierda W, Tran N, Keating MJ (2003) Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 101:3413–3415

    Article  PubMed  CAS  Google Scholar 

  60. Hale G, Waldmann H (1994) CAMPATH-1 monoclonal antibodies in bone marrow transplantation. J Hematother 3:15–31

    Article  PubMed  CAS  Google Scholar 

  61. Dinndorf PA, Andrews RG, Benjamin D, Ridgway D, Wolff L, Bernstein LD (1986) Expression of normal myeloid-associated antigens by acute leukemia cells. Blood 67:1048–1053

    PubMed  CAS  Google Scholar 

  62. Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 7:1490–1496

    PubMed  CAS  Google Scholar 

  63. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H, Karanes C, Theobald M, Bennett JM, Sherman ML, Berger MS, Eten CB, Loken MR, van Dongen JJ, Bernstein LD, Appelbaum FR, Mylotarg Study Group (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 19:3244–3254

    PubMed  CAS  Google Scholar 

  64. Leopold LH, Berger MS, Cheng SC, Cortes-Franco JE, Giles FJ, Estey EH (2003) Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse. Clin Adv Hematol Oncol 1:220–225

    PubMed  Google Scholar 

  65. Kung P, Goldstein G, Reinherz EL, Schlossman SF (1979) Monoclonal antibodies defining distinctive human T cell surface antigens. Science 206:347–349

    Article  PubMed  CAS  Google Scholar 

  66. [Anonymous] (1985) A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. Ortho Multicenter Transplant Study Group. N Engl J Med 313:337–342

    Google Scholar 

  67. Cosimi AB, Cho SI, Delmonico FL, Kaplan MM, Rohrer RJ, Jenkins RL (1987) A randomized clinical trial comparing OKT3 and steroids for treatment of hepatic allograft rejection. Transplant Proc 19:2431–2433

    PubMed  CAS  Google Scholar 

  68. Kremer AB, Barnes L, Hirsch RL, Goldstein G (1987) Orthoclone OKT3 monoclonal antibody reversal of hepatic and cardiac allograft rejection unresponsive to conventional immunosuppressive treatments. Transplant Proc 19:54–57

    PubMed  CAS  Google Scholar 

  69. [Anonymous] (2003) Adalimumab (humira) for rheumatoid arthritis. Med Lett Drugs Ther 45:25–27

    Google Scholar 

  70. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48:35–45

    Article  PubMed  CAS  Google Scholar 

  71. Choy G (1998) A review of respiratory syncytial virus infection in infants and children. Home Care Provid 3:306–311

    Article  PubMed  CAS  Google Scholar 

  72. Krilov LR (2002) Palivizumab in the prevention of respiratory syncytial virus disease. Expert Opin Biol Ther 2:763–769

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematopathology, Nichols Institute, Quest Diagnostics, San Juan Capistrano, CA

    Zhong J. Zhang & Maher Albitar

Authors
  1. Zhong J. Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maher Albitar
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. School of Life Sciences, University of Hertfordshire, Hatfield, Hertfordshire, UK

    John M. Walker (Professor Emeritus) & Ralph Rapley (Professor Emeritus) & 

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, a part of Springer Science+Business Media, LLC

About this protocol

Cite this protocol

Zhang, Z.J., Albitar, M. (2008). Monoclonal Antibodies. In: Walker, J.M., Rapley, R. (eds) Molecular Biomethods Handbook. Springer Protocols Handbooks. Humana Press. https://doi.org/10.1007/978-1-60327-375-6_33

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-375-6_33

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60327-370-1

  • Online ISBN: 978-1-60327-375-6

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation